Bosutinib Alternatives Compared
| Bosutinib | Gleevec (imatinib) | Tasigna (nilotinib) |
|
|---|
| Bosutinib | Gleevec (imatinib) | Tasigna (nilotinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Myelogenous Leukemia. Bosutinib may also be used for purposes not listed in this medication guide. |
Prescription only
Gleevec is an oral tyrosine kinase inhibitor that may be used to treat Ph+CML, Ph+ALL, and some other conditions. It may cause fluid retention, nausea, pain, headache, or blood abnormalities and... View more |
Prescription only
Prescribed for Chronic Myelogenous Leukemia. Tasigna may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Bosutinib | More about Gleevec (imatinib) | More about Tasigna (nilotinib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Bosutinib has an average rating of 7.9 out of 10 from a total of 7 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 14% reported a negative effect. |
Gleevec has an average rating of 8.6 out of 10 from a total of 37 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 5% reported a negative effect. |
Tasigna has an average rating of 7.7 out of 10 from a total of 30 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Bosutinib side effects |
View all Gleevec side effects |
View all Tasigna side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Gleevec prices |
View all Tasigna prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Bosulif | Other imatinib brands include: Imkeldi | Other nilotinib brands include: Danziten | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
22.5 hours |
40 hours |
17 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 571 drugs are known to interact with Bosutinib:
|
A total of 768 drugs are known to interact with Gleevec:
|
A total of 814 drugs are known to interact with Tasigna:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
September 04, 2012 |
May 10, 2001 |
October 29, 2007 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.